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Introduction 
The requirements for antimicrobial treatment to reach the central nervous system (CNS) are 
maximal, for two major reasons : i) the brain is an immuno-privileged site, with virtually no 
leukocytes in the brain parenchyma or cerebrospinal fluid (CSF) at baseline; ii) the blood-
brain barrier (BBB) drastically reduces the diffusion of antimicrobials into the CNS [1]. 
Treatment of CNS infections has been a major area of research since the discovery of the first 
antimicrobials. Treatment regimens recommended for encephalitis [2, 3], meningitis [4], and 
brain abscess [5], have to comply with the pharmacokinetic (PK), and pharmacodynamic (PD) 
characteristics of antibacterial, antiviral, antifungal, and antiparasitic agents available [6]. Due 
to the numerous constraints created by the BBB, therapeutic options are quite limited, so that 
current practices for treatment of CNS infections are remarkably similar worldwide, with 
much less heterogeneity than for other major infectious diseases (e.g. pneumonia, abdominal, 
or skin and skin structure infections). This paper summarizes the main parameters that must 
be taken into account to ensure efficacy of antimicrobial agents in the CNS, with an emphasis 
on antibacterial drugs.  
 
Physiology of the cerebrospinal fluid  
CSF is an ultrafiltrate of plasma that supports brain cells and eliminates waste products, 
acting as an alternate circulation system. The rate of CSF production in adult humans is 0.5 
mL/minute, two thirds originating from the choroid plexus, and one third from extracellular 
spaces of brain, and the spinal cord. Complete exchange of CSF occurs 5 times a day [7]. 
CNS infections have three major effects on CSF dynamics: i) increase in BBB permeability, 
proportionally to the extent of inflammation; ii) reduction of CSF flow, in association with 
higher intracranial pressure; iii) blockage of CSF flow sometimes also occurs when there is 
obstruction for example due to exudate at the basal cisterns. Antibiotics are not metabolized 
in the CSF, so that their concentrations and half-lives in this compartment depend on the 
balance between penetration, and elimination. Although drug concentrations in nervous 
tissue, extracellular space, and CSF may differ, CSF concentrations provide reliable estimates 
of drug concentrations in the CNS compartment as a whole.  
 
Blood-brain Barrier 
The functionality of the BBB has been illustrated by landmark experiments conducted by 
Ehrlich and colleagues 130 years ago. The intravenous injection of anilin dyes in animals was 
able to stain all organs, except the CNS. Conversely, injection of trypan blue in the CSF 
homogeneously tainted the brain and the spinal cord, but no other organ. The BBB consists of 
cerebral vascular endothelium of the arachnoid membrane, and the choroid plexus epithelium, 
which form a barrier of cells linked by tight junctions and surrounded by lipid layers. 
Diffusion of antimicrobials into the CNS mostly depends on their ability to cross the BBB and 
is inversely proportional to molecule size. The lipophilicity of a drug is another major 
determinant of CNS penetration. Diffusion of highly (fluoroquinolones, rifampin), or 
moderately (cefotaxime or ceftriaxone) lipophilic drugs is much higher than that of 
hydrophilic drugs (penicillins). Other factors determining CNS penetration include protein 
binding, and active transport.  
 
PK/PD of antimicrobials in CSF 
The PK of antimicrobials in the CNS has been investigated through complementary 
approaches. Simultaneous determination of the concentration of one antimicrobial agent in the 
plasma and in the CSF is often used to estimate its diffusion in the CNS, but such simple 
calculation has many drawbacks, as it provides variable, and often inaccurate estimates of 
CNS diffusion. Indeed, the timing of sampling has a major effect on these estimates, given 
that concentrations curves may be dramatically different in blood, and in CNS. With most 
antibiotics, the peak in the CSF occurs a few hours after the plasma peak, and the half-life is 
much longer in CSF than in plasma (e.g., cefotaxime half-life is 9.3 h in CSF vs. 0.7-1.4 h in 
blood [8]). Hence, if CNS and plasma are sampled close to the plasma peak, the diffusion rate 
will appear as <10%, while it would be estimated at >100% if sampled a few hours later, by 
the time of plasma trough, when CSF concentrations are still close to the peak [9]. CNS 
diffusion can only be reliably estimated through the ratio of area under curves (AUC) for CSF 
and plasma concentrations. This has been performed for a few antibacterial agents in animal 
models, and in patients with easy access to CNS (e.g. patients with external ventricular 
derivation), but both approaches have limitations: i) the PK of antimicrobial agents is often 
different in animals as compared to humans; ii) patients with external ventricular derivation 
have significant impairment in CSF production, and flow [10], so that data obtained in those 
patients may not be generalizable to the heterogeneous population of patients with CNS 
infections. CNS concentrations of antimicrobial agents may be heterogeneous, even within 
one compartment. Systemic administration of most drugs will lead to much higher 
concentrations in lumbar than in ventricular or cisternal CSF. Likewise, most drugs injected 
into the lumbar CSF do not reach therapeutic concentrations in ventricular CSF.  
 
Selected examples 
-lactam agents, although hydrophilic, are the backbone of most antibacterial treatment for 
CNS infections, despite a poor diffusion rate into the CSF at baseline (i.e., <15%). CNS 
efficacy of -lactam relies in two major assets: i) diffusion rate may dramatically increase 
with meningeal inflammation (e.g., from 2% to 20% for penicillins); ii) for selected -
lactams, tolerability allows the use of very high doses (e.g., until 24 g/day for cefotaxime, 
while the FDA-approved dose for uncomplicated infection is 2 g/day). Important exceptions 
must however be acknowledged: i) Imipenem increases the risk of seizures and should not be 
used for CNS infections; ii) -lactamase inhibitors (clavulanate, sulbactam, and tazobactam) 
are not suitable for treatment of CNS infections, as their CNS diffusion is low even in patients 
with meningitis, and CSF concentrations remains below the efficacy threshold; iii) data 
suggest that the poor CNS diffusion of several major anti-staphylococcal -lactams (e.g. 
cloxacillin, and cefazolin), precludes their use in this indication.  
Fluoroquinolones cumulate the assets for efficacy in CNS infection (lipophilic drugs, small 
molecules). However, tolerability of most fluoroquinolones restricts the use of high doses, so 
that their indications remain limited in CNS infection. 
Amphotericin B remains a mystery, in terms of CNS efficacy: although this compound is 
almost undetectable in CSF, or brain tissues, even in patients with meningeal inflammation 
treated with high doses, clinical studies have found that this is the most active agent for the 
treatment of cryptococcal meningitis. The particular metabolism of this antifungal agent may 
play a role in this unsolved enigma.  
 
Future developments 
New approaches have been identified in recent years for delivering drugs into the CNS, such 
as adenovirus-associated viruses mediated gene delivery, or nano-carriers for antibody 
treatment in neurodegenerative disease [11, 12]. Examples of nano-carriers include lipo-
carriers, carbon nanotubes, metal based carriers, polymers and emulsions, but the majority of 
these have only been tested in vitro and none were designed to transport anti-infectives across 
the BBB [12]. These new drug delivery methods may eventually also be used to improve 




CNS efficacy of antimicrobials is a complex issue, with multiple parameters involved. 
Defining the optimal treatment of CNS infections is one of the most challenging tasks for the 
intensivists: The therapeutic window is narrow, and the alternative drug options more limited 
than with any other severe infectious diseases. Progress has been achieved over recent years, 
especially with clinical studies on drug concentrations into the plasma and the CSF, but we 
still have a long way to go. Many unresolved issues remain to better define optimal treatment 
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1. Drugs with good CNS diffusion:
➢ Lipophilic molecules, small size







2. Drugs with moderate CNS diffusion:
➢ Hydro-lipophilic molecules, medium size 






3. Drugs with low CNS diffusion:
➢ Hydrophilic molecules, large size 






4. Drugs of no use in CNS infection:
➢ Hydrophilic molecules, large size 
➢ Not suitable for intraventricular
administration (toxicity, or no data)
- Echinocandins
- Macrolides
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